Results 51 to 60 of about 7,229 (203)
Journal of Medical Virology, Volume 98, Issue 9, September 2026.ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Syrine Boujamline +11 more
wiley +1 more source
, 2019 International audienceBackground: Rilpivirine is widely prescribed in people living with HIV. Although trough plasma concentrations have been associated with virological response, the drug pharmacodynamics remain incompletely characterized.Objectives: To
Lê, Minh Patrick +12 more
core +1 more source
Potent Inhibitors Active against HIV Reverse Transcriptase with K101P, a Mutation Conferring Rilpivirine Resistance [PDF]
, 2015 Catechol diether compounds have nanomolar antiviral and enzymatic activity against HIV with reverse transcriptase (RT) variants containing K101P, a mutation that confers high-level resistance to FDA-approved non-nucleoside inhibitors efavirenz and ...
Sarah B. Laskey (1515370) +19 more
core +1 more source
HIV/AIDS: Research and Palliative Care, 2012 Nimish Patel1, Christopher D Miller1,21Albany College of Pharmacy and Health Sciences, 2Albany Medical Center Division of HIV Medicine, Albany, NYAbstract: Fixed-dose combination tablets have become an important therapy option for patients infected with ...
Patel N, Miller CD,
doaj
Clinical Pharmacology: Advances and Applications, 2020 Rashmi Mehta,1 Joseph Piscitelli,2 Allen Wolstenholme,3 Caifeng Fu,4 Herta Crauwels,5 Brian Wynne,6 Kimberly Adkison7 1GlaxoSmithKline, Research Triangle Park, NC, USA; 2UNC Eshelman School of Pharmacy, Chapel Hill, NC, USA; 3GlaxoSmithKline ...
Mehta R +6 more
doaj
HIV Medicine, Volume 27, Issue 9, Page 1399-1420, September 2026.Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani +7 more
wiley +1 more source
Photophysical Exploration of Alectinib and Rilpivirine: Insights from Theory and Experiment
Molecules, 2023 Due to the excellent characteristics of fluorescence-based imaging, such as non-invasive detection of biomarkers in vitro and in vivo with high sensitivity, good spatio-temporal resolution and fast response times, it has shown significant prospects in ...
Chun Zhang +7 more
doaj +1 more source
HIV Medicine, Volume 27, Issue 9, Page 1421-1433, September 2026.Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning +16 more
wiley +1 more source
Enhancement of Solubility of Rilpivirine by Inclusion Complexation with Cyclodextrins
, 2018 Rilpivirine having lowest water solubility indicates class II drugs of BCS. These classes of drugs could potentially exhibit dissolution rate limited absorption.
Srivani Srivani +2 more
core +1 more source
Immunology, Volume 179, Issue 1, Page 138-148, September 2026.This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani +16 more
wiley +1 more source